1. Home
  2. TII vs SLN Comparison

TII vs SLN Comparison

Compare TII & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TII

Titan Mining Corporation

N/A

Current Price

$4.33

Market Cap

231.0M

Sector

N/A

ML Signal

N/A

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$5.41

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TII
SLN
Founded
2012
1994
Country
Canada
United Kingdom
Employees
N/A
116
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.0M
236.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TII
SLN
Price
$4.33
$5.41
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$6.25
$39.67
AVG Volume (30 Days)
561.3K
153.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.41
N/A
Revenue Next Year
$6.07
N/A
P/E Ratio
$25.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$1.97
52 Week High
$5.65
$7.78

Technical Indicators

Market Signals
Indicator
TII
SLN
Relative Strength Index (RSI) 59.62 57.17
Support Level $3.22 $5.07
Resistance Level $5.65 $6.04
Average True Range (ATR) 0.39 0.41
MACD 0.01 0.13
Stochastic Oscillator 82.61 82.77

Price Performance

Historical Comparison
TII
SLN

About TII Titan Mining Corporation

Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: